U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07943325) titled 'Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer' on Nov. 09.
Brief Summary: This study is a multicenter, randomized, open-label phase 3 trial of delayed administration of immunotherapy in patients who are planned to receive chemoimmunotherapy for newly diagnosed, advanced or metastatic, PD-L1 positive NSCLC without sensitizing alterations in EGFR, ALK, or ROS1.
Study Start Date: Feb., 2027
Study Type: INTERVENTIONAL
Condition:
Advanced NSCLC
Metastatic NSCLC - Non-Small Cell Lung Cancer
Intervention:
DRUG: Cisplatin
Dose per standard-of-care
DRUG: Carboplatin
Dose per standard-of-c...